Thursday October 18, 2018

Experimental Malaria Vaccine found to protect people in early clinical Trial: Study

In a recent clinical trial, an experimental Malaria vaccine has been found that can protect people when administered with antimalarial medication

0
//
71
A mosquito, Pixabay
Republish
Reprint

London, Feb 16, 2017: When administered together with antimalarial medication, an experimental malaria vaccine has been found to protect people in early clinical trial.

The study involved 67 healthy adult test persons, none of whom previously had malaria.

The best immune response was shown in a group of nine test persons who received the highest dose of the vaccine three times at four-week intervals.

At the end of the trial, all nine of these individuals had 100 per cent protection from the disease, according to the study published in the journal Nature.

NewsGram brings to you current foreign news from all over the world.

“By vaccinating with a live, fully active pathogen, it seems clear that we were able to set of a very strong immune response,” said study leader Benjamin Mordmueller from German Centre for Infection Research.

“Additionally, all the data we have so far indicate that what we have here is relatively stable, long-lasting protection,” Mordmueller said.

In the group of test persons who demonstrated 100 per cent protection after receiving a high dose three times, Mordmueller said, the protection was reliably still in place after 10 weeks — and remained measurable for even longer.

NewsGram brings to you top news around the world today.

The new vaccine showed no adverse effects on the test persons, Mordmueller said.

Malaria parasites are transmitted by the bite of female Anopheles mosquitoes. The Plasmodium falciparum parasite is responsible for most malaria infections and almost all deaths caused by the disease worldwide.

The vaccine, PfSPZ-CVac, developed by Sanaria Inc., of Rockville, Maryland, is administered intravenously to generate an immune response to protect against malaria infection.

The vaccine introduces live Plasmodium falciparum malaria parasites into the bloodstream.

Check out NewsGram for latest international news updates.

In this study, conducted at the University of Tubingen in Germany, oral antimalarial medication (chloroquine) was given simultaneously to prevent an actual malarial infection.

The researchers showed that PfSPZ-CVac induced a response from vaccine recipients’ T cells — white blood cells that activate the rest of the immune system — which was proportional to the dosage of the vaccine.

“That protection was probably caused by specific T-lymphocytes and antibody responses to the parasites in the liver,” Professor Peter Kremsner from Institute of Tropical Medicine, University of Tubingen.

The researchers said their next step is to further test the vaccine’s effectiveness over several years in a clinical study in Gabon. (IANS)

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

USA: Everything you want to know about Security Clearance; Find out here!

A security clearance allows a person access to classified national security information or restricted areas.

0
Former CIA Director John O. Brennan speaks at the Council on Foreign Relations in Washington, March 11, 2014. President Donald Trump revoked Brennan's security clearance Wednesday. VOA
Former CIA Director John O. Brennan speaks at the Council on Foreign Relations in Washington, March 11, 2014. President Donald Trump revoked Brennan's security clearance Wednesday. VOA

U.S. President Donald Trump on Wednesday revoked the security clearance of former CIA Director John Brennan. We take a look at what that means.

What is a security clearance?

A security clearance allows a person access to classified national security information or restricted areas after completion of a background check. The clearance by itself does not guarantee unlimited access. The agency seeking the clearance must determine what specific area of information the person needs to access.

What are the different levels of security clearance?

There are three levels: Confidential, secret and top secret. Security clearances don’t expire. But, top secret clearances are reinvestigated every five years, secret clearances every 10 years and confidential clearances every 15 years.

All federal agencies follow a list of 13 potential justifications for revoking or denying a clearance. VOA
All federal agencies follow a list of 13 potential justifications for revoking or denying a clearance. VOA

Who has security clearances?

According to a Government Accountability Office report released last year, about 4.2 million people had a security clearance as of 2015, they included military personnel, civil servants, and government contractors.

Why does one need a security clearance in retirement?

Retired senior intelligence officials and military officers need their security clearances in case they are called to consult on sensitive issues.

Also Read: Governments Across The World Request Apple for 30,000 Device Information

Can the president revoke a security clearance?

Apparently. But there is no precedent for a president revoking someone’s security clearance. A security clearance is usually revoked by the agency that sought it for an employee or contractor. All federal agencies follow a list of 13 potential justifications for revoking or denying a clearance, which can include criminal acts, lack of allegiance to the United States, behavior or situation that could compromise an individual and security violations. (VOA)